Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
Myelodysplastic syndromes
SEER-Medicare
azacitidine
effectiveness
hypomethylating agents (HMA)
survival
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
28
12
2019
medline:
28
4
2021
entrez:
28
12
2019
Statut:
ppublish
Résumé
Hypomethylating agents (HMA) showed overall survival (OS) benefits in patients with higher-risk myelodysplastic syndromes (HR-MDS) in clinical trials. We conducted a retrospective cohort study of Surveillance, Epidemiology, and End Results (SEER)-Medicare data of patients ≥66 years diagnosed with refractory anemia with excess blasts (RAEB), a proxy for HR-MDS, in 01/2001-04/2004 (pre-period) or 01/2006-12/2011 (post-period). Association between post-period diagnosis and OS was examined using propensity scores (PS)-matched samples. Among 1876 RAEB patients, median OS was 9 months and 30.8% received HMAs (3.6% in pre-period; 43.0% in post-period) with no association between post-period diagnosis and OS. In the top PS quartile, post-period diagnosis was associated with a 74% lower risk of death (Hazard ratio [HR] = 0.26, 95%-CI: 0.10-0.69,
Identifiants
pubmed: 31878809
doi: 10.1080/10428194.2019.1703970
pmc: PMC7735409
mid: NIHMS1547725
doi:
Substances chimiques
Azacitidine
M801H13NRU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1178-1187Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : N02 PC015105
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35136
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35139
Pays : United States
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Blood. 2018 Feb 15;131(7):818-821
pubmed: 29259002
Cancer. 2017 Oct 1;123(19):3662-3672
pubmed: 28759108
J Natl Cancer Inst. 2008 Nov 5;100(21):1542-51
pubmed: 18957672
Cancer. 2006 Apr 15;106(8):1794-803
pubmed: 16532500
Leukemia. 2015 Dec;29(12):2449-51
pubmed: 26369829
BMJ Open. 2018 Jul 23;8(7):e019955
pubmed: 30037860
J Clin Oncol. 2006 Aug 20;24(24):3895-903
pubmed: 16921040
Cancer. 2016 May 15;122(10):1598-607
pubmed: 26970288
Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):357-367
pubmed: 28239929
J Geriatr Oncol. 2013 Apr;4(2):157-65
pubmed: 23795223
J Clin Oncol. 2011 May 20;29(15):1987-96
pubmed: 21483003
Blood Cancer J. 2018 Jun 11;8(6):55
pubmed: 29891916
Blood Cancer J. 2016 Apr 08;6:e414
pubmed: 27058229
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87
pubmed: 28040720
Med Care. 2014 Jun;52(6):500-10
pubmed: 24638118
Br J Haematol. 2016 Dec;175(5):829-840
pubmed: 27650975
Leuk Lymphoma. 2017 Apr;58(4):982-985
pubmed: 27558206
Am J Hematol. 2018 Oct;93(10):1245-1253
pubmed: 30051599
Leukemia. 2016 Mar;30(3):649-57
pubmed: 26464171
J Clin Oncol. 2017 Aug 20;35(24):2745-2753
pubmed: 28486043
Cancer. 2011 Jun 15;117(12):2697-702
pubmed: 21656747
Leuk Lymphoma. 2020 Feb;61(2):397-408
pubmed: 31570040
Blood Rev. 2019 Mar;34:1-15
pubmed: 30314642
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Leuk Lymphoma. 2015 Apr;56(4):887-95
pubmed: 24956145
Blood. 2019 Feb 7;133(6):521-529
pubmed: 30545832
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Leukemia. 2015 Sep;29(9):1875-81
pubmed: 25943181
Health Serv Res. 1998 Dec;33(5 Pt 1):1337-60
pubmed: 9865223